1. Indications
PLAQUENIL (hydroxychloroquine sulfate tablets) is indicated for:
• the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, in
adult patients who have not responded satisfactorily to drugs with less potential for
serious side effects.
• the suppressive treatment and treatment of acute attacks of malaria due to P. vivax, P.
malariae, P. ovale, and susceptible strains of P. falciparum. PLAQUENIL is not active against
the exo-erythrocytic forms of P. vivax, P. malariae and P. ovale, and therefore will neither
prevent infection due to these organisms when given prophylactically, nor prevent relapse
of infection due to these organisms. PLAQUENIL is highly effective as a suppressive agent in
patients with vivax or malariae malaria in terminating acute attacks and significantly
lengthening the interval between treatment and relapse. In patients with falciparum
malaria, PLAQUENIL abolishes the acute attack and effects complete cure of the infection,
unless due to a resistant strain of P. falciparum (see 7 Warnings and Precautions, General,
Malaria).
1.1. Pediatrics
Pediatrics (< 18 y…
https://pdf.hres.ca/dpd_pm/00083189.PDF
PM date: 2026-01-16
Source product: PLAQUENIL; DIN 02017709; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.